Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are heterogeneous intestinal
diseases that threaten the health of an increasing number of individuals as their lifestyles …

Changes in the composition of gut-associated microbial communities are associated with
many human illnesses, but the factors driving dysbiosis remain incompletely understood …

Inflammatory bowel diseases (IBD) develop via convergence of environmental, microbial,
immunological, and genetic factors. Alterations in the gut microbiota have been associated …

The gut microbiota is a complex and plastic consortium of microorganisms that are intricately
connected with human physiology. The liver is a central immunological organ that is …

Background The gut microbiome is associated with the response to immunotherapy for
different cancers. However, the impact of the gut microbiome on hepatobiliary cancers …

Over the past two decades, bile acids (BAs) have become established as important
signaling molecules that enable fine-tuned inter-tissue communication from the liver, their …

Determining the structure and phenotypic context of molecules detected in untargeted
metabolomics experiments remains challenging. Here we present reverse metabolomics as …

Inflammatory bowel diseases (IBD) arise from a convergence of genetic risk, environmental
factors, and gut microbiota, where each is necessary but not sufficient to cause disease …

Inflammatory bowel disease (IBD) has become a global disease with accelerating incidence
worldwide in the 21st century while its accurate etiology remains unclear. In the past …

The intestinal microbiome is a key determinant of responses to biologic therapy in
inflammatory bowel disease (IBD). However, diverse therapeutics and variable responses …